

Members Obtain Free CE Credits from JCP Articles!



Loperamide: A Readily Available but Dangerous Opioid Substitute

September 2019 – *The Journal of Clinical Pharmacology* (JCP)

Why is this article important to you?

Following the completion of this activity, learners will gain further insight into the role and extent of specific CYP450 and P-glycoprotein inhibitors on loperamide elimination, as well as the subsequent drug-drug interactions and risk profiles. Learners will gain insight to learn the appropriate risk management options for the adverse events of loperamide.



CPE Accreditation Statement

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

UAN: 0238-0000-19-038-H05-P – ACPE 1 Contact Hours

Activity Type: Knowledge-based **Format:** Home-study **Target Audience:** 'P'



ACCME Accreditation Statement

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ACCME Designation Statement

The Accreditation Council for Continuing Medical Education designates this journal CE activity for 1 *AMA PRA Category 1™* credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience

Interprofessional team of Physicians, Pharmacists, PhDs, Nurse Practitioners and Physician Assistants.

Learning Objectives

After completing this activity, the learner will be able to:

1. Understand the risk profile when loperamide is taken above the recommended dose for opioid abuse;
2. Understand which drugs can alter the risk profile of loperamide due to drug-drug interactions and when they should be avoided;
3. Understand public health options for de-risking loperamide overdose;
4. Understand the options of treating loperamide-induced Torsade de Pointes.

Requirements to Receive Credit

In order to receive continuing medical education (CME) or continuing pharmacy education (CPE) credit, the learner must register for the educational activity, study the provided journal article, complete the online learning Post-event Self-assessment as well as the online course Evaluation and CME/CPE Certificate. Credits and CME/CPE Certificates must be claimed within thirty (30) days of completing the article, Post-event Self-Assessment and Evaluation. Contact CE@ACCP1.org with any questions.

Disclosures:

Article Selection: Joseph S. Bertino Jr, PharmD, FCP, FCCP, Editor-in-Chief, JCP and Owner, Bertino Consulting Inc, selected the article for this course and has nothing to disclose.

Planner: Li Zhang, MD, PhD, Associate Director, Clinical Pharmacology, AstraZeneca, is an employee of AstraZeneca plc and Sanofi. Dr. Zhang owns stocks at Sanofi.

CE Reviewer: Claude Abdallah, MD, MSc, FASA, Associate Professor, Anesthesiology, Children's National Health System. Dr. Abdallah has nothing to disclose.

Schedule & Fees

JCP monthly Journal CE articles are generally released on the 1st or 2nd Tuesday of each month. They are priced in packages of January to December for each year. Packages are available at no cost to ACCP Members and \$75/calendar year to Non-members. Once you register, you have access to all of the Journal CE articles for the calendar year.

Acknowledgement of Financial Support

No financial support was received for this educational activity.

Home Study Initial Release and Expiration Dates

Date of Issuance: 9/1/2019

Expiration Date: 12/31/2022

Helpful Tips

Download the article and access the Self-assessment Post-test, Evaluation and Certificate [here](#).

Learn how to print your CME/CPE Certificate [here](#).
